<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00621907</url>
  </required_header>
  <id_info>
    <org_study_id>0708097</org_study_id>
    <secondary_id>2007-006275-36</secondary_id>
    <nct_id>NCT00621907</nct_id>
  </id_info>
  <brief_title>Study : LEVOBUPIVACAINE Versus Placebo</brief_title>
  <acronym>LEVOBU</acronym>
  <official_title>Levobupivacïne Into Post-analgesia : Randomized Monocentric Study Against Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The locoregional anaesthesia is increasingly important in surgical practice, often allowing
      to simplify per- and post-operative analgesia. caesarian occurs in 20 % of delivery leading
      to a longer hospitalization because of the pain resulting from the surgery. The
      Levobupivacaïne (Chirocaïne) administered through catheters placed in the caesarean scars,
      showed its efficiency in post-operative analgesia.

      Method : realization of a double blind prospective randomized study, control versus placebo
      Purpose : to show that the local administration of a unique dose of analgesia reduce the
      post-operative pain with a little or non-invasive technique
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be done at the department of Obstétric and gynecology, in the CHU of
      Saint-Etienne. It will include all patients requiring a caesarean without any
      contraindication.

      All the patients requiring a urgent or a very urgent caesarean will be excluded because a
      rapid consent can't be obtained and the product preparation can't be done.

      Inclusion after information and minimum one hour of time for consideration. Randomization :
      the teatment group will be randomized according to the patient number : control versus
      placebo : 70 patients in the group infiltration of levobupivacaïne and 70 patients in the
      group infiltration of a placebo. Every product will be prepared in a 30 ml syringe filled
      with levobupivacaïne or 0,9 % sodium chloride depending on the group of randomization. All
      patients will get their caesarean according to the same technique, then, before the cutaneous
      close, the product will be injected in the caesarean wall.

      Fllow-up : supervision of the pain (morphine consumption, VAS) and of undesirable effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>analgesic consumption of level 3 in the two treated groups</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual analogic scale (VAS) at rest or on rising, early rehabilitation, residual pain 2 months after the operation</measure>
    <time_frame>hours : 1, 2, 3, 4, 5, 6, 8, 12, 24, 48 and at 2 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient who received levobupivacaïne</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient who received placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chirocaine (Levobupivacaine)</intervention_name>
    <description>levobupivacaine 0,5 % 30 ml infiltration (150 mg)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium chloride</intervention_name>
    <description>sodium chloride : 0,9% 30 ml</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  all patients requiring a non-urgent caesarian done according to the Misgav-Ladach
             technique

        Exclusion Criteria:

          -  Patients requiring very urgent caesarian

          -  allergic to levobupivacaïne

          -  with previous history of alcoholism or drug addiction

          -  with severe hypotension or an ischemic cardiopathy badly compensated or thyrotoxicoses

          -  treated with first generation of IMAO (monoamine oxidase inhibitor) or with
             anti-arrhytmia drugs with anesthesic activity
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Céline CHAULEUR, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <last_update_submitted>September 15, 2010</last_update_submitted>
  <last_update_submitted_qc>September 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Clément CAILLAUX</name_title>
    <organization>Centre Hospitalo-Universitaire de Saint-Etienne</organization>
  </responsible_party>
  <keyword>randomized</keyword>
  <keyword>analgesic</keyword>
  <keyword>caesarean scars</keyword>
  <keyword>locoregional anaesthesia</keyword>
  <keyword>infiltration</keyword>
  <keyword>levobupivacaïne</keyword>
  <keyword>Chirocaïne</keyword>
  <keyword>caesarian</keyword>
  <keyword>unique administration</keyword>
  <keyword>post-caesarian analgesic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

